Improved survival and MRD remission with blinatumomab vs. chemotherapy in children with first high-risk relapse B-ALL

Franco Locatelli; G. Zugmaier; C. Rizzari; J. D. Morris; B. Gruhn; T. Klingebiel; R. Parasole; C. Linderkamp; C. Flotho; A. Petit; C. Micalizzi; Y. Zeng; R. Desai; W. N. Kormany; C. Eckert; A. Moricke; M. Sartor; O. Hrusak; C. Peters; V. Saha; L. Vinti; A. von Stackelberg

doi:10.1038/s41375-022-01770-3

Improved survival and MRD remission with blinatumomab vs. chemotherapy in children with first high-risk relapse B-ALL

Franco Locatelli^*
, G. Zugmaier
, C. Rizzari
, J. D. Morris
, B. Gruhn
, T. Klingebiel
, R. Parasole
, C. Linderkamp
, C. Flotho
, A. Petit
, C. Micalizzi
, Y. Zeng
, R. Desai
, W. N. Kormany
, C. Eckert
, A. Moricke
, M. Sartor
, O. Hrusak
, C. Peters
, V. Saha

L. Vinti, A. von Stackelberg

^*Autore corrispondente per questo lavoro

Amgen Incorporated
University of Milan - Bicocca
Universitaetsklinikum Jena
Goethe University Frankfurt
Azienda Ospedaliera Santobono Pausillipon
Hannover Medical School
University of Freiburg
Hôpital Armand Trousseau
Istituto Pediatrico di Ricovero e Cura a Carattere Scientifico G Gaslini
IQVIA Inc.
Charité – Universitätsmedizin Berlin
Westmead Hospital
Charles University
St. Anna Kinderspital
University of Manchester

Risultato della ricerca: Contributo in rivista › Articolo

Abstract

NO ABSTRACT

Lingua originale	Inglese
pagine (da-a)	222-225
Numero di pagine	4
Rivista	Leukemia
Volume	37
Numero di pubblicazione	1
DOI	https://doi.org/10.1038/s41375-022-01770-3
Stato di pubblicazione	Pubblicato - 2023

All Science Journal Classification (ASJC) codes

Ematologia
Oncologia
Ricerca sul Cancro

Keywords

BLINATUMOMAB

Accesso al documento

10.1038/s41375-022-01770-3

Altri file e collegamenti

Cita questo

Locatelli, F., Zugmaier, G., Rizzari, C., Morris, J. D., Gruhn, B., Klingebiel, T., Parasole, R., Linderkamp, C., Flotho, C., Petit, A., Micalizzi, C., Zeng, Y., Desai, R., Kormany, W. N., Eckert, C., Moricke, A., Sartor, M., Hrusak, O., Peters, C., ... von Stackelberg, A. (2023). Improved survival and MRD remission with blinatumomab vs. chemotherapy in children with first high-risk relapse B-ALL. Leukemia, 37(1), 222-225. https://doi.org/10.1038/s41375-022-01770-3

@article{e76adb53af6f4813ae65bdaa97555d5a,

title = "Improved survival and MRD remission with blinatumomab vs. chemotherapy in children with first high-risk relapse B-ALL",

abstract = "NO ABSTRACT",

keywords = "BLINATUMOMAB, BLINATUMOMAB",

author = "Franco Locatelli and G. Zugmaier and C. Rizzari and Morris, \{J. D.\} and B. Gruhn and T. Klingebiel and R. Parasole and C. Linderkamp and C. Flotho and A. Petit and C. Micalizzi and Y. Zeng and R. Desai and Kormany, \{W. N.\} and C. Eckert and A. Moricke and M. Sartor and O. Hrusak and C. Peters and V. Saha and L. Vinti and \{von Stackelberg\}, A.",

year = "2023",

doi = "10.1038/s41375-022-01770-3",

language = "English",

volume = "37",

pages = "222--225",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Springer Nature",

number = "1",

}

Locatelli, F, Zugmaier, G, Rizzari, C, Morris, JD, Gruhn, B, Klingebiel, T, Parasole, R, Linderkamp, C, Flotho, C, Petit, A, Micalizzi, C, Zeng, Y, Desai, R, Kormany, WN, Eckert, C, Moricke, A, Sartor, M, Hrusak, O, Peters, C, Saha, V, Vinti, L & von Stackelberg, A 2023, 'Improved survival and MRD remission with blinatumomab vs. chemotherapy in children with first high-risk relapse B-ALL', Leukemia, vol. 37, n. 1, pagg. 222-225. https://doi.org/10.1038/s41375-022-01770-3

TY - JOUR

T1 - Improved survival and MRD remission with blinatumomab vs. chemotherapy in children with first high-risk relapse B-ALL

AU - Locatelli, Franco

AU - Zugmaier, G.

AU - Rizzari, C.

AU - Morris, J. D.

AU - Gruhn, B.

AU - Klingebiel, T.

AU - Parasole, R.

AU - Linderkamp, C.

AU - Flotho, C.

AU - Petit, A.

AU - Micalizzi, C.

AU - Zeng, Y.

AU - Desai, R.

AU - Kormany, W. N.

AU - Eckert, C.

AU - Moricke, A.

AU - Sartor, M.

AU - Hrusak, O.

AU - Peters, C.

AU - Saha, V.

AU - Vinti, L.

AU - von Stackelberg, A.

PY - 2023

Y1 - 2023

N2 - NO ABSTRACT

AB - NO ABSTRACT

KW - BLINATUMOMAB

UR - https://publicatt.unicatt.it/handle/10807/229144

UR - https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=85143596062&origin=inward

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85143596062&origin=inward

U2 - 10.1038/s41375-022-01770-3

DO - 10.1038/s41375-022-01770-3

M3 - Article

SN - 0887-6924

VL - 37

SP - 222

EP - 225

JO - Leukemia

JF - Leukemia

IS - 1

ER -

Improved survival and MRD remission with blinatumomab vs. chemotherapy in children with first high-risk relapse B-ALL

Abstract

All Science Journal Classification (ASJC) codes

Keywords

Accesso al documento

Altri file e collegamenti

Fingerprint

Cita questo